Navigation Links
Caliper Life Sciences to Present at Jefferies 2011 Global Healthcare Conference
Date:5/31/2011

HOPKINTON, Mass., May 31, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP) today announced that its presentation at the Jefferies 2011 Global Life Sciences Conference, will be webcast on Wednesday, June 8 at 11:00 a.m. EDT.  Kevin Hrusovsky, President and CEO of Caliper, will be providing an update on the company's business. The live webcast can be accessed at http://www.wsw.com/webcast/jeff60/calp/.  An archived presentation will be available for 90 days.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently.  Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease.  Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions.  For more information please visit www.caliperLS.com.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Caliper Life Sciences to Webcast Investor Session of Open House
2. Caliper Life Sciences Reports First Quarter 2011 Results
3. Caliper Life Sciences to Present at the 36th Annual Deutsche Bank Health Care Conference
4. Caliper Life Sciences First Quarter Results Conference Call Notice
5. Caliper Life Sciences Announces Date and Location of its 2011 Annual Meeting of Stockholders
6. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
7. Caliper Life Sciences and HistoRx to Provide Integrated Solutions for Superior Protein Quantification of Biomarkers in Tissue
8. Analysis of Calipers Phase I EPA ToxCast™ Data Published in Leading Scientific Journal
9. Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing
10. Caliper Life Sciences Fourth Quarter and Fiscal Year 2010 Financial Results Conference Call Notice
11. Caliper Life Sciences IVIS® Optical Imaging System Adoption Surpasses 1000 Units: Validated Drug Research, Discovery and Development Tool Enables Advances in Personalized Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... 31 Millennium Pharmaceuticals, The Takeda,Oncology Company, today ... of VELCADE based therapies that showed consistently high,complete ... multiple,myeloma (MM). CR is one of the best ... for oral presentation at the American Society,of Clinical ...
... reduced the risk of cancer returning or death by 36% beyond clinical ... alone(1) - Findings may allow clinicians to improve standard of care ... ... - These are the first data from a large clinical program exploring ...
Cached Medicine Technology:Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 2Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 3Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 4Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 5Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 6Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 7Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 2Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 3Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 4Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 5Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 6Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 7Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 8Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 9
(Date:4/23/2014)... a researcher from the Cancer Science Institute of Singapore ... identified the cancer specific stem cell which causes gastric ... new drugs for the treatment of this disease and ... by Dr Chan Shing Leng, Research Assistant Professor at ... cancer-specific variant of a cell surface protein, CD44v8-10, marks ...
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where different ... signatures within the same cancer. Such differences could ... strategies. , Firstly they confirmed the mutual exclusivity ... or BRAF mutation. Secondly, they found that lung ... that specific mutation present uniformly throughout the tumour, ...
(Date:4/23/2014)... to the bottom of Alzheimer,s disease has been ... and controversies. In the latest crook in the ... into the interaction between proteins associated with the ... ACS Chemical Neuroscience , could have important ... Surewicz, Krzysztof Nieznanski and colleagues explain that for ...
(Date:4/22/2014)... recently FDA-approved device has been shown to reduce seizures ... 50 percent. When coupled with an innovative electrode placement ... facilitated the complete elimination of seizures in nearly half ... clinical trials. , That,s good news for a large ... living with epilepsy whose seizures can,t be controlled with ...
(Date:4/22/2014)... UT Southwestern Medical Center are making breakthroughs that could ... A team of physician-scientists at UT Southwestern has identified ... natural anti-depressant properties) works inside the brain. Simultaneously, the ... in the form of a neuroprotective drug known as ... April,s issue of Molecular Psychiatry, is notable ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3
... in no real danger, survey finds , MONDAY, Aug. 20 ... white peers to take risks that boost their odds for ... August issue of the journal Archives of Dermatology , ... Medicine surveyed 369 high school students (221 white Hispanics and ...
... are exposed to more pro-tobacco advertising, according to a ... this months Public Health Reports. , Smoking remains ... the United States, causing more than 440,000 deaths annually ... indirect costs each year; African-Americans currently bear the greatest ...
... In a study likely applicable to men of other ... than 21 drinks per week) may increase the risk ... study are published in the latest issue of Annals ... Lydia Bazzano of Tulane University School of Public Health ...
... sounds like the latest cleaning sensation being hawked on ... get in your eyes. , But a few properly ... to diagnosing dry eye syndrome earlier than other methods, ... disease, new research at UT Southwestern Medical Center confirms. ...
... to new treatments, study says , SUNDAY, Aug. 19 ... most red, purple and blue fruits and vegetables, may help ... , In laboratory tests on rats and on human colon ... the growth of colon cancer cells. The team also found ...
... It affected 4 indicators of cardiovascular trouble, study found ... air drags down a number of "biological indicators" pointing ... shows. , The indicators include autonomic dysfunction, inflammation, oxidative ... was published Aug. 15 in the American Journal ...
Cached Medicine News:Health News:Hispanic Teens Take More Skin Cancer Risks 2Health News:Pitt study finds inequality in tobacco advertising 2Health News:Eye-staining technique offers early detection for dry eye syndrome 2Health News:Eye-staining technique offers early detection for dry eye syndrome 3Health News:Urban Smog Tough on Young Adults' Hearts 2
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: